Clinical Trials
92 trialsNCT02231749 2026-05-27
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Bristol-Myers Squibb
Phase 3 Completed
NCT07431281 2026-05-27
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT03520686 2026-05-26
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 3 Terminated
NCT07405164 2026-05-26
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06561386 2026-05-20
RELATIVITY1093
Bristol-Myers Squibb
Phase 3 Recruiting
NCT07541170 2026-05-15
KRASCENDO 3
Hoffmann-La Roche
Phase 3 Not yet recruiting
NCT04987203 2026-05-08
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 3 Completed
NCT05568095 2026-05-08
STAR-221
Arcus Biosciences, Inc.
Phase 3 Active not recruiting
NCT07195695 2026-05-06
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Boehringer Ingelheim
Phase 3 Recruiting
NCT06097728 2026-04-28
eVOLVE-Meso
AstraZeneca
Phase 3 Recruiting
NCT06743126 2026-04-21
SUPRAME
Immatics US, Inc.
Phase 3 Recruiting
NCT05317858 2026-04-16
LIMITLESS
InSightec
Phase 3 Recruiting
NCT03661320 2026-04-15
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04099251 2026-04-09
CheckMate76K
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04039607 2026-04-06
CheckMate 9DW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT05907122 2026-03-27
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
Amgen
Phase 3 Completed
NCT07000149 2026-03-10
eVOLVE-RCC02
AstraZeneca
Phase 3 Active not recruiting
NCT03036098 2026-03-06
CheckMate901
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03143153 2026-02-17
CheckMate 648
Bristol-Myers Squibb
Phase 3 Completed
NCT03873402 2026-01-21
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT06054555 2026-01-12
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
Amgen
Phase 3 Active not recruiting
NCT05002569 2026-01-08
RELATIVITY-098
Bristol-Myers Squibb
Phase 3 Terminated
NCT02998528 2026-01-06
CheckMate 816
Bristol-Myers Squibb
Phase 3 Completed
NCT03215706 2025-12-17
CheckMate 9LA
Bristol-Myers Squibb
Phase 3 Completed
NCT05111626 2025-12-15
FORTITUDE-102
Amgen
Phase 3 Active not recruiting
NCT03383458 2025-11-21
CheckMate 9DX
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT02743494 2025-11-18
CheckMate 577
Bristol-Myers Squibb
Phase 3 Completed
NCT02477826 2025-10-30
CheckMate 227
Bristol-Myers Squibb
Phase 3 Completed
NCT03906071 2025-10-21
SAPPHIRE
Mirati Therapeutics Inc.
Phase 3 Completed
NCT02632409 2025-10-16
CheckMate 274
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04025879 2025-10-16
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04810078 2025-10-09
CheckMate-67T
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04008030 2025-10-03
CheckMate 8HW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04674683 2025-09-24
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
HUYABIO International, LLC.
Phase 3 Active not recruiting
NCT04149574 2025-09-16
CheckMate 7G8
Bristol-Myers Squibb
Phase 3 Terminated
NCT03937219 2025-09-10
COSMIC-313
Exelixis
Phase 3 Active not recruiting
NCT05625399 2025-08-24
RELATIVITY-127
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT02872116 2025-08-07
CheckMate649
Bristol-Myers Squibb
Phase 3 Completed
NCT04026412 2025-07-24
CheckMate73L
Bristol-Myers Squibb
Phase 3 Completed
NCT06640530 2025-07-08
UNIVERSE
Biocad
Phase 3 Active not recruiting
NCT03522246 2025-06-24
ATHENA
pharmaand GmbH
Phase 3 Active not recruiting
NCT02667587 2025-06-18
CheckMate548
Bristol-Myers Squibb
Phase 3 Completed
NCT04100018 2025-06-12
CheckMate 7DX
Bristol-Myers Squibb
Phase 3 Completed
NCT03141177 2025-06-06
CheckMate 9ER
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT01844505 2025-05-21
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
Bristol-Myers Squibb
Phase 3 Completed
NCT02388906 2025-04-24
CheckMate 238
Bristol-Myers Squibb
Phase 3 Completed
NCT02017717 2025-04-04
CheckMate 143
Bristol-Myers Squibb
Phase 3 Completed
NCT03635983 2025-04-01
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
Bristol-Myers Squibb
Phase 3 Completed
NCT05297565 2025-02-27
CheckMate-6GE
Bristol-Myers Squibb
Phase 3 Completed
NCT02576509 2025-02-17
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
Bristol-Myers Squibb
Phase 3 Completed